Navigation Links
Important Deadlines Near for $21 Million Class Action Settlement That Provides Consumers With Money Back for Over 200 Prescription Drugs
Date:3/3/2009

BOSTON, March 3 /PRNewswire-USNewswire/ -- Important deadlines are approaching for class members of a proposed class action settlement related to the average wholesale prices of certain prescription drugs. The United States District Court for the District of Massachusetts granted preliminary approval of the Proposed Settlement in July 2008. In the lawsuit, In re: Pharmaceutical Industry Average Wholesale Price Litigation, No. 01-CV-12257-PBS, MDL No. 1456, plaintiffs claimed that drug manufacturers unlawfully inflated the published average wholesale price of certain drugs, increasing what certain consumers and others paid. The defendants deny any wrongdoing.

Consumers who paid percentage co-payments or full payments for any of the covered drugs between January 1, 1991 and March 1, 2008 are eligible for money back. (A percentage co-payment varies with the cost of the drug; refunds are not available to those who paid flat co-payments.) Requests to be excluded from the Settlement and objections to the Settlement must be postmarked by March 16, 2009. Consumer Class Members must file claims by May 1, 2009.

The Proposed Settlement includes approximately $21.8 million for payments to consumers who file valid claims. Qualifying consumers can get a minimum of $35 by certifying under oath that they paid percentage co-payments for the covered drugs. Or, with receipts or bills for percentage co-payments for the covered drugs, they can receive more money back. For some of the drugs, the payment is up to three times the amount of the co-payment.

The approximately 200 covered drugs are used for the treatment of many medical conditions and are often, but not always, injected in a doctor's office or clinic. The drugs include those for treatment of cancer, HIV, asthma, allergies, infections, inflammation, pain, gastrointestinal, lung and blood issues, and other conditions.

The Defendants, 11 drug manufacturers, deny any wrongdoing, and have stated that while they believe they have strong defenses to the claims asserted, they have entered into the Settlement as a reasonable way to resolve the litigation and avoid the further expense, burden, and inconvenience that would result if they continued to litigate.

The Court will hold a Final Approval Hearing on April 27, 2009 at 2:00 p.m. to consider whether the Proposed Settlement is fair, reasonable, and adequate and the motion for attorneys' fees and expenses. For detailed information, including a list of all the covered drugs and a claim form, call toll-free 1-877-465-8136, visit www.AWPTrack2Settlement.com, or write: AWP Track 2 Settlement Administrator, P.O. Box 951, Minneapolis, MN 55440-0951.


'/>"/>
SOURCE AWP Track 2 Settlement Administrator
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Educational materials increase knowledge and behaviors important for preventing shaken baby syndrome
2. Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever
3. HealthyPlace.com, the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder
4. Iron overload: An important co-factor in the development of liver disease in alcoholics
5. Concentric Medical Reaches Important Stroke Milestone
6. Berman Calls Obamas Mexico City Policy Reversal an Important Step in Womens Rights, Health Care
7. E. coli engineered to produce important class of antibiotic, anti-cancer drugs
8. Most Important Factors Driving Usage of Antibiotics in the ICU Setting are Availability in Intravenous Formulation, Activity Against Key Gram Negative Pathogens, Drug Interactions and Bactericidal Activity
9. Outpatient Service Facilities Face Increasing Competition - Patient Perceptions More Important Than Ever
10. Radio Interview Opportunity: Important News for Seniors
11. Important Message for 2008 Universal Childrens Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... ... Film Studios. With inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ... position, rotation, columns, rows, ranks, point, lines, polygons, polygon texture animation, opacity texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... Monday, May 16, 2016, at its new location in the Exchange Furniture Mall at ... a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
(Date:4/27/2016)... April 27, 2016 ... Forums in Zürich gab Strekin AG den ... STR001 zur Erhaltung des Resthörvermögens von Patienten, ... Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden ... STR001 wird während der Operation direkt ins ...
Breaking Medicine Technology: